Qiagen N.V. $QGEN Shares Acquired by Natixis Advisors LLC

Natixis Advisors LLC boosted its position in Qiagen N.V. (NYSE:QGEN) by 8.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,308,697 shares of the company’s stock after acquiring an additional 106,347 shares during the quarter. Natixis Advisors LLC’s holdings in Qiagen were worth $58,473,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Qiagen by 1.9% during the third quarter. Vanguard Group Inc. now owns 9,424,809 shares of the company’s stock worth $420,401,000 after acquiring an additional 172,062 shares during the last quarter. Norges Bank acquired a new position in shares of Qiagen in the 2nd quarter valued at about $158,728,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Qiagen by 5.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,874,356 shares of the company’s stock worth $133,140,000 after purchasing an additional 141,393 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH increased its position in Qiagen by 18.2% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 2,334,083 shares of the company’s stock worth $103,372,000 after purchasing an additional 360,153 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in Qiagen by 0.5% in the second quarter. Sei Investments Co. now owns 1,812,002 shares of the company’s stock valued at $87,085,000 after buying an additional 8,746 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Stock Down 2.7%

Shares of NYSE:QGEN opened at $43.36 on Tuesday. The company has a market capitalization of $9.16 billion, a price-to-earnings ratio of 21.50, a price-to-earnings-growth ratio of 2.17 and a beta of 0.70. The company has a 50 day moving average of $49.80 and a two-hundred day moving average of $49.11. Qiagen N.V. has a 52-week low of $40.14 and a 52-week high of $57.81. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44.

Qiagen (NYSE:QGEN) last posted its earnings results on Thursday, February 5th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The business had revenue of $540.42 million for the quarter, compared to analysts’ expectations of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.61 earnings per share. As a group, analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QGEN has been the topic of a number of recent research reports. Wall Street Zen raised shares of Qiagen from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Stifel Nicolaus set a $50.00 target price on shares of Qiagen and gave the company a “hold” rating in a research note on Friday, February 6th. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Barclays set a $58.00 price target on shares of Qiagen and gave the stock an “overweight” rating in a research report on Friday, February 6th. Finally, Citigroup cut their price objective on Qiagen from $55.40 to $55.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Four investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and an average target price of $55.20.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.